NCT02898116 Phase 1/2 Study of Ensartinib and Durvalumab, in ALK-rearranged Non-small Cell Lung Cancer Status COMPLETED Phase PHASE1/PHASE2
NCT02890849 Clinical Research for the Consistency Analysis of PD-L1 in Cancer Tissue and Plasma Exosome Status COMPLETED Phase NA
NCT02869685 Consistency Analysis of PD-L1s in Advanced NSCLC Tissues and in Plasma Exosomes Before and After Radiotherapy Status COMPLETED Phase NA
NCT02856893 Osimertinib Treatment on EGFR T790M Plasma Positive NSCLC Patients (APPLE) Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT02795884 Adjuvant Erlotinib Intercalating Chemotherapy or Adjuvant Chemotherapy Alone in NSCLC With Common EGFR Mutation Status WITHDRAWN Phase PHASE3
NCT02766348 Clinical Efficacy and Safety of Dendritic Cytotoxic Lymphocyte(DC-CTL) Cell Infusion in NSCLC Patients Status UNKNOWN Phase PHASE2
NCT02759614 Compare Bevacizumab in Combination With Erlotinib Versus Erlotinib Alone in NSCLC Patients Activating EGFR Mutations Status COMPLETED Phase PHASE3
NCT02691299 A Phase III Clinical Trial of Fruquintinib in Patients With Advanced Non-small Cell Lung Cancer Status COMPLETED Phase PHASE3
NCT02648724 Sym015 (Anti-MET) in Patients With Advanced Solid Tumor Malignancies Status COMPLETED Phase PHASE1/PHASE2
NCT02631460 S1 vs.Pemetrexed Plus Carboplatin in Patients With EGFR Wild Type Stage IIIB or IV Nonsquamous NSCLC Status UNKNOWN Phase PHASE2
NCT02607813 Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations Status TERMINATED Phase PHASE1
NCT02573259 A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors Status COMPLETED Phase PHASE1
NCT02563548 A Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab in Participants With Selected Hyaluronan High Solid Tumors Status COMPLETED Phase PHASE1
NCT02526537 Gefitinib for EGFR Sensitive Mutation Postoperative Stage Ib NSCLC Patients Status TERMINATED Phase N/A
NCT02515032 Pilot Study of Safety and Tolerability of Nutrifriend Cachexia in NSCLC Cachexia Status COMPLETED Phase NA
NCT02500199 Phase I Study of Pyrotinib in Patients With HER2-positive Solid Tumors Status UNKNOWN Phase PHASE1